“People with diabetes are 10 to 20 times more likely to go blind than someone without the condition, due to diabetic retinopathy. However, if this condition is detected early through an eye examination and treated, blindness can be prevented in 90% of cases”
Patients with proliferative diabetic retinopathy (PDR) exhibit marked visual dysfunction and structural changes in both the inner and outer retinal layers, research findings indicate. Retinal function was evaluated using a number of tests, including contrast sensitivity, frequency doubling perimetry (FDP) and photostress testing. And semiautomatically segmented spectral-domain optical coherence tomography scans were used to quantify…
Studies in mouse models of night blindness have demonstrated that vision can be restored by transplanting rod precursor cells taken from mouse neonates directly into the retina of recipient animals. The University College London (UCL) Institute of Ophthalmology-led team showed that the transplanted rod cells made synaptic connections with the existing retinal circuitry, were light…
Cells taken from the donated eyes of dead people may be able to give sight to the blind, researchers suggest. Tests in rats, reported in Stem Cells Translational Medicine, showed the human cells could restore some vision to completely blind rats. Donated corneas are already used to improve some people’s sight, but the team at…
CAMBRIDGE, Mass.–(BUSINESS WIRE)– Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that the Data Monitoring Committee (DMC) for the Phase 3 APOLLO study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN) met on October 7, 2016 and recommended continuation of the trial without modification. Read the entire article here.
Kala Pharmaceuticals, Inc. (Kala), a developer of innovative ophthalmic products based on its proprietary mucus-penetrating particle (MPP) technology, today announced positive top-line results from a Phase 2 clinical trial of KPI-121. KPI-121 achieved statistical significance for the primary sign endpoint of bulbar conjunctival hyperemia, and promising trends were observed for key symptom endpoints. “The achievement of…
Oklahoma City, OK, and Seattle, WA; (May 4, 2015) – eyecro LLC and NeuMedics Inc., today announced the formation of a collaboration to facilitate development of NM108, a first-in-class small molecule to treat a number of ophthalmic disorders that lead to blindness, including Diabetic Retinopathy. The collaboration grants NeuMedics full access to the MiDROPS™ formulation…